169M fTV, a Boston-based digital health company, announced today that it has raised $200 million in Series C funding led by GV (formerly Google Ventures). The round also included participation from new investors B Capital Group and Coatue Management, as well as existing investors NEA, F-Prime Capital Partners, and Lux Capital.
169M fTV’s platform provides a comprehensive view of a patient’s health history, including clinical data, imaging, and wearable device data. The platform uses machine learning and artificial intelligence to identify patterns and trends in the data that can help clinicians diagnose diseases earlier and more accurately, and develop more personalized treatment plans.
The company’s platform is currently being used by over 100 hospitals and healthcare systems in the United States. The new funding will be used to expand the company’s sales and marketing team, and to develop new features and integrations for its platform.
“We are excited to partner with GV and our other investors to help us expand our digital health platform and make it available to more patients and clinicians,” said Dan Elron, CEO and co-founder of 169M fTV. “Our platform is already helping clinicians to diagnose diseases earlier and more accurately, and to develop more personalized treatment plans. We believe that this new funding will allow us to accelerate our growth and make a significant impact on the future of healthcare.”
GV Partner Will Glaser will join 169M fTV’s board of directors in conjunction with the funding round.
“169M fTV is building a next-generation digital health platform that has the potential to revolutionize the way that patients are diagnosed and treated,” said Glaser. “We are excited to partner with Dan and the team to help them achieve their vision.”
169M fTV was founded in 2014 by Dan Elron and Dr. Nir Gavrielov. The company has raised over $300 million in funding to date.